{"name":"Syngene International","slug":"syngene-international","ticker":"SYNGENE.NS","exchange":"NSE","domain":"syngeneintl.com","description":"Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services. It provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigil","hq":"Bengaluru, India","founded":0,"employees":"","ceo":"","sector":"CRO / CDMO / Contract Research","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":467.95,"stockChange":4.7,"stockChangePercent":1.01,"marketCap":"$2.0B","metrics":{"revenue":390452555.89570564,"revenueGrowth":1.8,"grossMargin":75.4,"rdSpend":0,"netIncome":33074683.930886403,"cash":134627639.9073408,"dividendYield":0.27,"peRatio":53.4,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":12,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"yahoo_finance","revenue":366860585.3,"revenuePeriod":"2025-03-31","revenueHistory":[{"period":"2025-03-31","value":366860585.3},{"period":"2024-03-31","value":351894996.0625},{"period":"2023-03-31","value":321681842.07500005},{"period":"2022-03-31","value":261788154.51250002}],"grossProfit":268430244.3625,"grossProfitHistory":[{"period":"2025-03-31","value":268430244.3625},{"period":"2024-03-31","value":254749210.2375},{"period":"2023-03-31","value":231846532.50000003},{"period":"2022-03-31","value":183566058.63750002}],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":20082922.6125,"operatingIncome":64071102.56250001,"operatingIncomeHistory":[{"period":"2025-03-31","value":64071102.56250001},{"period":"2024-03-31","value":67580131.16250001},{"period":"2023-03-31","value":64561948.825},{"period":"2022-03-31","value":45366726.900000006}],"netIncome":51820833.075,"netIncomeHistory":[{"period":"2025-03-31","value":51820833.075},{"period":"2024-03-31","value":53262041.25000001},{"period":"2023-03-31","value":48499788.150000006},{"period":"2022-03-31","value":41335521.425000004}],"eps":12.34,"epsHistory":[{"period":"2025-03-31","value":12.34},{"period":"2024-03-31","value":12.69},{"period":"2023-03-31","value":11.51},{"period":"2022-03-31","value":9.82}],"cash":38317339.087500006,"cashHistory":[{"period":"2025-03-31","value":38317339.087500006},{"period":"2024-03-31","value":8939668.100000001},{"period":"2023-03-31","value":9085877.625},{"period":"2022-03-31","value":27257632.875000004}],"totalAssets":709732364.9625001,"totalLiabilities":216087234.41250002,"totalDebt":60353203.212500006,"equity":493645130.55,"operatingCashflow":121938743.85000001,"operatingCashflowHistory":[{"period":"2025-03-31","value":121938743.85000001},{"period":"2024-03-31","value":108832104.28750001},{"period":"2023-03-31","value":86002531.3125},{"period":"2022-03-31","value":60635178.725}],"capex":-80425682.28750001,"capexHistory":[{"period":"2025-03-31","value":-80425682.28750001},{"period":"2024-03-31","value":-53345589.550000004},{"period":"2023-03-31","value":-54128854.862500004},{"period":"2022-03-31","value":-49659020.8125}],"freeCashflow":41513061.5625,"dividendsPaid":-5253099.362500001,"buybacks":null,"employees":0,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":null,"ebit":4208745.612500001,"ebitda":16083047.750000002,"period":"2025-12-31","revenue":95777682.41250001,"epsBasic":0.37,"netIncome":1566530.625,"rdExpense":null,"epsDiluted":0.37,"grossProfit":71820207.3875,"operatingIncome":12396479.012500001},{"sga":null,"ebit":11790753.8375,"ebitda":23403967.5375,"period":"2025-06-30","revenue":91328735.4375,"epsBasic":2.16,"netIncome":9054547.012500001,"rdExpense":null,"epsDiluted":2.15,"grossProfit":68603597.8375,"operatingIncome":10443537.5},{"sga":null,"ebit":26369932.1875,"ebitda":37450525.475,"period":"2025-03-31","revenue":92780387.15,"epsBasic":null,"netIncome":19143004.2375,"rdExpense":null,"epsDiluted":null,"grossProfit":68238074.025,"operatingIncome":25534449.1875},{"sga":null,"ebit":20176914.450000003,"ebitda":31529039.712500002,"period":"2024-12-31","revenue":98555663.3875,"epsBasic":3.27,"netIncome":13691477.662500001,"rdExpense":null,"epsDiluted":3.26,"grossProfit":73762705.36250001,"operatingIncome":18088206.950000003},{"sga":null,"ebit":15707080.4,"ebitda":27288963.4875,"period":"2024-09-30","revenue":93051919.125,"epsBasic":2.64,"netIncome":11080593.287500001,"rdExpense":null,"epsDiluted":2.64,"grossProfit":68342509.4,"operatingIncome":13534824.600000001}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":467.95,"previousClose":463.25,"fiftyTwoWeekHigh":728.6,"fiftyTwoWeekLow":380,"fiftyTwoWeekRange":"380.0 - 728.6","fiftyDayAverage":422.73,"twoHundredDayAverage":560.6,"beta":0.03,"enterpriseValue":1877362864.785408,"forwardPE":36.6,"priceToBook":3.97,"priceToSales":5.03,"enterpriseToRevenue":4.81,"enterpriseToEbitda":18.35,"pegRatio":0,"ebitda":102284004.9382272,"ebitdaMargin":26.2,"freeCashflow":75795279.76746881,"operatingCashflow":95579255.2,"totalDebt":47873175.900000006,"debtToEquity":9.5,"currentRatio":1.38,"returnOnAssets":4.8,"returnOnEquity":6.6,"analystRating":"2.1 - Buy","recommendationKey":"buy","numberOfAnalysts":8,"targetMeanPrice":578.12,"targetHighPrice":835,"targetLowPrice":410,"dividendRate":1.25,"payoutRatio":0.14,"fiveYearAvgDividendYield":0,"exDividendDate":1782259200,"insiderHeldPercent":53,"institutionHeldPercent":38.2,"sharesOutstanding":401751784,"floatShares":174948016,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":8.76,"epsForward":12.79,"revenuePerShare":92.91,"bookValue":117.84,"officers":[{"age":72,"name":"Dr. Kiran  Mazumdar-Shaw B.Sc (Hons), B.Sc.","title":"Executive Chairperson"},{"age":68,"name":"Mr. Peter James Jonathan Bains","title":"CEO, MD & Director"},{"age":null,"name":"Mr. Deepak  Jain","title":"Chief Financial Officer"},{"age":null,"name":"Mr. Gaurav  Kushwaha","title":"Chief Technology Officer"},{"age":null,"name":"Dr. Jayashree  Aiyar Ph.D.","title":"Chief Scientific Officer"},{"age":null,"name":"Mr. G.  Krishnan","title":"Head of Investor Relations"},{"age":null,"name":"Mr. Chethan  Yogesh","title":"Company Secretary & Compliance Officer"},{"age":50,"name":"Mr. Surender Kumar Sharma","title":"General Counsel"}],"industry":"Diagnostics & Research","irWebsite":"","website":"https://www.syngeneintl.com","phone":"91 80 6891 8000"}}